The group’s principal activity is set up the in vitro intact HCV virus culturing system, which could continuously replicate the HCV virus in vitro. In January 2006, the group acquired Hunan Hua Yang Pharmaceutical Co. Ltd. The group operates from China. In the year 2006, the group’s total revenue was $386,916.
